DexCom, Inc. officer Sadie Stern filed a Form 144 notice of proposed sale dated October 27, 2026, disclosing plans to sell 2,565 shares of DexCom common stock with an aggregate market value of $201,660.30.

Key Highlights

  • Proposed sale: Sadie Stern, an officer of DexCom, Inc., intends to sell 2,565 shares of common stock with an aggregate market value of $201,660.30.
  • Approximate date of sale: October 27, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares acquired: The 2,565 shares were acquired on March 8, 2024, as restricted stock from the issuer, with payment noted as "Not Applicable."
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of May 28, 2026.
  • Prior sales in past 3 months: Stern sold 2,565 shares on September 28, 2026, for gross proceeds of $220,974.75, and 2,565 shares on August 27, 2026, for gross proceeds of $226,669.05.
  • Shares outstanding: According to the filing, 377,360,765 shares of DexCom common stock were outstanding at the time of the notice.

DexCom Officer Sadie Stern Discloses Proposed Rule 144 Share Sale

According to the Form 144 filed with the U.S. Securities and Exchange Commission on October 27, 2026, Sadie Stern, identified as an officer of DexCom, Inc. (NASDAQ:DXCM), proposed to sell 2,565 shares of the company's common stock. The aggregate market value of the proposed sale was listed as $201,660.30. The intended broker for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing discloses that the shares subject to the proposed sale were originally acquired on March 8, 2024, as restricted stock directly from the issuer. The nature of payment at acquisition was listed as "Not Applicable." Stern indicated reliance on a Rule 10b5-1 written trading plan, with an adoption date of May 28, 2026. The filing notes that by signing the form, Stern represents that she does not know any material adverse information regarding the current and prospective operations of DexCom that has not been publicly disclosed, as of the plan adoption date.

The filing also discloses two prior sales by Stern in the past three months: 2,565 shares sold on September 28, 2026, generating gross proceeds of $220,974.75, and 2,565 shares sold on August 27, 2026, generating gross proceeds of $226,669.05. DexCom, Inc. is headquartered at 6340 Sequence Drive, San Diego, California 92121, with SEC file number 000-51222.

What Was Disclosed

Sadie Stern, an officer of DexCom, Inc., filed a Form 144 on October 27, 2026, proposing to sell 2,565 shares of common stock valued at $201,660.30, acquired as restricted stock in March 2024, under a Rule 10b5-1 plan adopted May 28, 2026.